The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from 2017 to 2025. All this comes from a report published by Transparency Market Research. From a global perspective, North America accounts for a leading share in the market due to rising instances of chronic diseases, increasing research investment and technological progress. The stem cells market in North America is projected to be worth USD 167.33 Billion by 2025.
The lead analyst of the report explains, “The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market.”
One stem cell play we like a lot is BioRestorative Therapies, Inc.,(BRTX) a life sciences company focused on stem cell-based therapies, recently reported positive findings from Defined Health, which was engaged by the Company to conduct an independent review of BRTX-100, the Company’s lead cell therapy candidate designed to treat chronic Lumbar Disc Disease (cLDD). Defined Health is a business development and strategy consulting firm that has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.